FierceBiotechElstar Therapeutics Closes $39M Series A Financing to Support Development of its Universal Targeted Immunotherapy …Business Wire (press release)CAMBRIDGE, Mass.–(BUSINESS WIRE)–Elstar Therapeutics, a company fulfilling the promise of p… Continue reading
Head to Head Contrast: OptiNose (OPTN) and Editas Medicine (EDIT)The Ledger GazetteIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic aci… Continue reading
Gene therapy improves visionAOPPatients with the inherited retinal condition, Leber congenital amaurosis (LCA), showed improvements in their vision following gene therapy treatment. Pioneering research revealed that 27 of the 29 patients who were treat… Continue reading
Organovo (ONVO) vs. Editas Medicine (EDIT) Financial ContrastTrueBlueTribuneIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA)… Continue reading
The Indian ExpressStem cell therapy advancement offers treatment for blindnessThe Indian ExpressScientists, led by a person of Indian origin, have made advances in efforts to make stem cell-derived retinal cells used to treat age-related macular degene… Continue reading
The Ledger Gazette |
CRISPR Therapeutics Announces Proposed Public Offering of Common Shares
GlobeNewswire (press release) ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq:CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced that it is … Crispr Therapeutics’ (CRSP) “Hold” Rating Reaffirmed at CannThe Ledger Gazette Looking for stock with Analysts Rating? CRISPR Therapeutics AG (CRSP)Wall Street Morning Unusual Activity Sighted in CRISPR Therapeutics AG (:CRSP) SharesThe Herald |